Spero Therapeutics (NASDAQ:SPRO) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a report issued on Friday,Benzinga reports.

SPRO has been the subject of a number of other research reports. HC Wainwright dropped their price target on Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, November 4th. TD Cowen raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th.

Spero Therapeutics Price Performance

NASDAQ:SPRO traded down $0.07 during trading hours on Friday, reaching $1.18. 465,372 shares of the company were exchanged, compared to its average volume of 218,831. The company has a market capitalization of $63.71 million, a P/E ratio of 3.58 and a beta of 0.63. The business has a 50 day moving average of $1.29 and a 200 day moving average of $1.36. Spero Therapeutics has a 1-year low of $1.01 and a 1-year high of $1.89.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in shares of Spero Therapeutics during the first quarter worth $31,000. Renaissance Technologies LLC increased its holdings in Spero Therapeutics by 14.2% in the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after purchasing an additional 121,492 shares in the last quarter. Acadian Asset Management LLC raised its position in Spero Therapeutics by 121.8% in the first quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock valued at $1,310,000 after purchasing an additional 418,742 shares during the last quarter. Murchinson Ltd. boosted its stake in shares of Spero Therapeutics by 1.3% during the first quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock valued at $1,503,000 after purchasing an additional 11,210 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Spero Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after purchasing an additional 9,675 shares during the last quarter. Institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.